Laboratorios Biopas
- Biotech or pharma, therapeutic R&D
Swixx Biopharma Group is the leading comercialization platform for rare disease, onco-hemo, CNS and specialty biopharma in CEE, Greece, MENA and Latin America (via our subsidiary Biopas, also presenting at the 2025 Bio US conference) and Eurasia / Russia.
The Swixx Group has combined net sales of 1.4 Billion Euros in 2025 and is growing fast. We have 1,900 employees and real presence in 44 countries, with strong local teams. At Bio US, we seek multi-regional late Phase 3 / FDA & EMA registered products ready for access, unlicensed sales and commercialization opportunities, as well as M&A and licensing.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}